Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 8/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671145 | 1.00 | ACE (0.59) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL29613833 | 0.91 | ACE (0.56) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL29573143 | 0.91 | ACE (0.56) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL215178 | 0.91 | ACE (0.56) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL268002 | 0.91 | ACE (0.56) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL215179 | 0.91 | ACE (0.56) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL8130117 | 0.90 | CTSS (0.54) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL19341835 | 0.90 | CTSS (0.54) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL5045604 | 0.89 | ACE (0.48) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL9551322 | 0.89 | ACE (0.72) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9205126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205124-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-8716322-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716322-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140050737-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140031297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ACE 433/4885CTSS 177/4885CTSK 227/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | ACE 611/4885CTSS 125/4885CTSK 171/4885 |
| US-20140050737-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ACE 433/4885CTSS 177/4885CTSK 227/4885 |
| US-20140031297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ACE 433/4885CTSS 177/4885CTSK 227/4885 |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | ACE 527/4885CTSS 88/4885CTSK 205/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | ACE 433/4885CTSS 177/4885CTSK 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.